Circulation and degradation of GIP and GLP-1

Hormone and Metabolic Research

Volumn 36, Issue 11-12, 2004, Pages 761-765

  Deacon, C F ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dipeptidyl peptidase IV; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Gut hormone; Incretin; Neutral endopeptidase 24.11

Indexed keywords

AMINOPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; MEMBRANE METALLOENDOPEPTIDASE; PROTEINASE; UNCLASSIFIED DRUG;

ENZYME ACTIVITY; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; INTESTINE CELL; INTESTINE WALL; LIVER CELL; METABOLITE; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

ADENOSINE DEAMINASE; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD26; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLYCOPROTEINS; HUMANS; KIDNEY; LIVER; MOLECULAR SEQUENCE DATA; NEPRILYSIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 12244281855     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826160     Document Type: Review

References (61)

1. Buchan AM, Polak JM, Capella C, Solcia E, Pearse AG. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry 1978; 56: 37-44
2. Damholt AB, Kofod H, Buchan AM. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res 1999; 298: 287-293
3. Mortensen K, Christensen LL, Holst JJ, Ørskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003; 114: 189-196
4. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992; 22: 283-291
5. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716-718
6. Lund PK, Goodman RH, Dee PC, Habener JF. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 1982; 79: 345-349
7. Ørskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535-539
8. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-619
9. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol 2000; 278: E1010-E1018
10. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002; 172: 355-362
11. Ørkov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes. 1993; 42: 658-661
12. Wettergren A, Pridal L, Wojdermann M, Holst JJ. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul Pept 1998; 77: 83-87
13. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957
14. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596
15. Pridal L, Deacon CF, Kirk O, Christensen JV, Carr RD, Holst JJ. Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36) amide in dogs and is degraded more quickly in vitro by dog plasma. Eur J Drug Metab Pharmacokinet 1996; 21: 51-59
16. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996; 318: 429-435
17. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem 1996; 271: 23222-23229
18. Takeda J, Seino Y, Tanaka K, Fukumoto H, Kayano T, Takahashi H, Mitani T, Kurono M, Suzuki T, Tobe T, Imura H. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci USA 1987; 84: 7005-7008
19. Tseng CC, Jarboe LA, Landau SB, Williams EK, Wolfe MM. Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat. Proc Natl Acad Sci USA 1993; 90: 1992-1996
20. Burhol PG, Jorde R, Waldum HL. Radioimmunoassay of plasma gastric inhibitory polypeptide (GIP), release of GIP after a test meal and duodenal infusion of bile, and immunoreactive plasma GIP components in man. Digestion 1980; 20: 336-345
21. Krarup T, Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 1984; 9: 35-46
22. Krarup T, Holst JJ, Larsen KL. Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat. Am J Physiol. 1985; 249: E195-E200
23. Otte SC, Mutt V, McIntosh CHS, Brown JC. Purification and amino acid composition of an 8000 dalton immunoreactive form of GIP. Dig Dis Sci 1984; 29 (Suppl): 63S (abstract)
24. Jörnvall H, Carlquist M, Kwauk S, Otte SC, McIntosh CH, Brown JC, Mutt V. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett 1981; 123: 205-210
25. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-3581
26. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744
27. Gutniak MK, Linde B, Holst JJ, Efendic S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 1994; 17: 1039-1044
28. Nauck MA, Wollschlager D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553
29. Buckley DI, Lundquist P. Analysis of the degradation of insulinotropin [GLP-1 (7-37)] in human plasma and production of degradation resistant analogs. Reg Pept 1992; 40: 117 (abstract)
30. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835
31. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O. Structure-activity studies of glucagon-like peptide-1. J Biol Chem 1994; 269: 6275-6278
32. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24
33. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131
34. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002; 172: 355-362
35. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220-224
36. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53: 654-662
37. Hansen L, Deacon CF, Ørskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356-5363
38. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97: 6874-6879
39. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998; 47: 764-769
40. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001; 50: 1588-1597
41. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42: 1324-1331
42. Pedersen RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998; 47: 1253-1258
43. Ahrén B, Holst JJ, Marensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404: 239-245
44. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002; 51: 943-950
45. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875
46. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084
47. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Goke R, Goke B, Thole H, Zimmermann B, Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995; 58: 149-156
48. Hupe-Sodmann K, Goke R, Goke B, Thole HH, Zimmermann B, Voigt K, McGregor GP. Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides 1997; 18: 625-632
49. Plamboeck A, Holst JJ, Carr RD, Deacon CF. The degradation of glucagon-like peptide-1 involves both dipeptidyl peptidase IV and neutral endopeptidase 24.11 in vivo. Regul Pept 2004; 122: 6 (Abstract)
50. O'Dorisio TM, Sirinek KR, Mazzaferri EL, Cataland S. Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism 1977; 26: 651-656
51. Sirinek KR, O'Dorisio TM, Gaskill HV, Levine BA. Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. Am J Surg 1984; 148: 732-735
52. Ørskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 1992; 74: 379-384
53. Jorde R, Burhol PG, Gunnes P, Schulz TB. Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats. Scand J Gastroenterol 1981; 16: 469-471
54. Ruiz-Grande C, Alarcon C, Alcantara A, Castilla C, Lopez Novoa JM, Villanueva-Penacarrillo ML, Valverde I. Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 1993; 25: 612-616
55. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 271: E458-E464
56. Simonsen L. A comparison of the metabolism of GLP-1 and exendin-4 - focus on the role of the kidney. Masters thesis, Faculty of Health Sciences, University of Copenhagen, 2004
57. Carone FA, Peterson DR, Flouret G. Renal tubular processing of small peptide hormones. J Lab Clin Med 1982; 100: 1-14
58. Emmanouel DS, Jaspan JB, Rubenstein AH, Huen AH, Fink E, Katz AI. Glucagon metabolism in the rat. J Clin Invest 1978; 62: 6-13
59. Hanks JB, Andersen DK, Wise JE, Putnam WS, Meyers WC, Jones RS. The hepatic extraction of gastric inhibitory polypeptide and insulin. Endocrinology 1984; 115: 1011-1018
60. Chap Z, O'Dorisio TM, Cataland S, Field JB. Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs. Dig Dis Sci 1987; 32: 280-284
61. Elovson J. Biogenesis of plasma membrane glycoproteins. Purification and properties of two rat liver plasma membrane glycoproteins. J Biol Chem 1980; 255: 5807-5815